Shares of Outlook Therapeutics cratered to $0.68 — down 41% in a single week — after a one-two punch of dismal third-quarter results and a heavily dilutive stock offering forced investors to reckon with the gap between a regulatory milestone and commercial reality.

  • Revenue Collapsed to Nearly Zero Despite European Sales

Revenue plummeted to $9,000, a steep decline from $1.51 million in the same quarter last year and well below forecasts by nearly $1 million.

Analysts had expected $1.20 million in revenue. The company's eye-disease drug has been selling in Europe since 2024, yet quarterly sales collapsed to a rounding error. That signals European traction is stalling, not building — a troubling sign just months before the far larger U.S. launch.

  • A $55 Million Lifeline That Floods the Market With New Shares

The company issued approximately 55.6 million shares of common stock, along with warrants — rights to buy additional shares — for the same number, at a combined price of $0.99 per share.

Those warrants carry an exercise price of $1.10 and are immediately exercisable for five years. To put this in perspective, shares outstanding were roughly 104.6 million as of March 31. The new issuance, plus warrant conversions, could more than double the share count, slashing each existing investor's ownership stake. Net proceeds came to roughly $51.1 million.

  • The Cash Cushion Is Thin and the Clock Is Ticking

Cash stood at just $11.2 million as of June 30, excluding offering proceeds. Even with the fresh capital, the company is burning through cash rapidly — posting a $20.3 million net loss for the quarter alone.

Management still targets a U.S. launch by year-end 2026, with projected revenue potential exceeding $500 million by 2030. But at this burn rate, the combined war chest buys roughly three quarters of runway — meaning another raise may be needed before meaningful U.S. sales begin.

  • Analyst Targets Reveal a Market Deeply Split on the Story

BTIG upgraded to Buy in July with a $4 target, while HC Wainwright and Chardan hold neutral stances at $1.60 and $1, respectively.

A critical milestone is the reimbursement-code application due by October 1, 2026 — this will determine whether U.S. insurers cover the drug and, ultimately, whether revenue ramps at all. Until that code is secured and prescriptions flow, the stock remains a bet on execution with a balance sheet that leaves almost no room for delay.